IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0482335
(2002-07-01)
|
등록번호 |
US-8197839
(2012-06-12)
|
우선권정보 |
AU-PR6024 (2001-06-29) |
국제출원번호 |
PCT/AU02/00866
(2002-07-01)
|
§371/§102 date |
20040629
(20040629)
|
국제공개번호 |
WO03/009833
(2003-02-06)
|
발명자
/ 주소 |
- Martinod, Serge R.
- Brandon, Malcolm
|
출원인 / 주소 |
|
대리인 / 주소 |
Morgan, Lewis & Bockius LLP
|
인용정보 |
피인용 횟수 :
1 인용 특허 :
17 |
초록
▼
A sustained release apparatus including at least one sustained release mini tablet implant; the or each mini tablet implant including a pharmaceutically active composition including at least one pharmaceutically active component; and a carrier therefor, wherein the or each tablet implant is of the c
A sustained release apparatus including at least one sustained release mini tablet implant; the or each mini tablet implant including a pharmaceutically active composition including at least one pharmaceutically active component; and a carrier therefor, wherein the or each tablet implant is of the coated tablet or covered rod type; the or each mini tablet implant being approximately 0.1 to 0.5 times the length and/or diameter of a single immediate release tablet capable of providing the desired threshold blood level depending on the pharmaceutical active selected, and having a payload of approximately 30% to 70% by weight of the total payload of an equivalent immediate release treatment conducted for an equivalent period; the sustained release apparatus providing, in use, zero order release of pharmaceutical active.
대표청구항
▼
1. A sustained release apparatus comprising a plurality of sustained release mini tablet implants; each mini tablet implant comprising a pharmaceutically active composition comprising at least one pharmaceutically active component; anda carrier therefor;wherein the carrier is a sugar or mineral salt
1. A sustained release apparatus comprising a plurality of sustained release mini tablet implants; each mini tablet implant comprising a pharmaceutically active composition comprising at least one pharmaceutically active component; anda carrier therefor;wherein the carrier is a sugar or mineral salt or mixture thereof,wherein each mini tablet implant is of the coated tablet type;each mini tablet implant being approximately 0.1 to 0.5 times the length and/or diameter of a single immediate release tablet capable of providing the desired threshold blood level depending on the pharmaceutically active component selected, andhaving a payload of approximately 30% to 70% by weight of the total payload of an equivalent immediate release treatment conducted for an equivalent period;the sustained release apparatus providing, in use, zero order release of pharmaceutically active component;each mini-tablet implant being of insufficient size and/or payload individually to provide a predetermined desired threshold blood level of pharmaceutically active component for treatment of a selected indication. 2. A sustained release apparatus according to claim 1, wherein the payload is approximately 30% to 50% by weight of that of an equivalent immediate release treatment. 3. A sustained release apparatus according to claim 1, wherein each mini tablet implant further comprises a sustained release support material, the pharmaceutically active composition being carried in or on the sustained release support material. 4. A sustained release apparatus according to claim 1, wherein each mini tablet implant takes the form of a coated compressed tablet. 5. A sustained release apparatus according to claim 1, wherein each mini tablet implant is approximately 0.20 to 0.25 times the length and/or diameter of single immediate release size tablet, capable of providing the desired threshold blood level depending on the pharmaceutically active component selected. 6. A sustained release apparatus according to claim 1, wherein each sustained release mini tablet implant is of generally circular cylindrical configuration with a cross-sectional diameter of approximately 0.1 to 4 mm and an axial length of approximately 0.1 to 20 mm. 7. A sustained release apparatus according to claim 6 wherein the axial length of each mini tablet implant is approximately 0.25 to 5 mm. 8. A sustained release apparatus according to claim 1, wherein the pharmaceutically active composition comprises at least one pharmaceutically active component selected from the group consisting of acetonemia preparations, anabolic agents, anaesthetics, analgesics, anti-acid agents, anti-arthritic agents, antibodies, anti-convulsivants, anti-fungals, anti-histamines, anti-infectives, anti-inflammatories, anti-microbials, anti-parasitic agents, anti-protozoals, anti-ulcer agents, antiviral pharmaceuticals, behaviour modification drugs, biologicals, blood and blood substitutes, bronchodilators and expectorants, cancer therapy and related pharmaceuticals, cardiovascular pharmaceuticals, central nervous system pharmaceuticals, coccidiostats and coccidiocidals, contraceptives, contrast agents, diabetes therapies, diuretics, fertility pharmaceuticals, growth hormones, growth promoters, hematinics, hemostatics, hormone replacement therapies, hormones and analogs, immunostimulants, minerals, muscle relaxants, natural products, nutraceuticals and nutritionals, obesity therapeutics, ophthalmic pharmaceuticals, osteoporosis drugs, pain therapeutics, peptides and polypeptides, respiratory pharmaceuticals, sedatives and tranquilizers, transplantation products, urinary acidifiers, vaccines and adjuvants and vitamins. 9. A sustained release apparatus according to claim 8, wherein the growth hormone is a natural or synthetic human, bovine, ovine or porcine growth hormone. 10. A sustained release apparatus according to claim 8 wherein the pharmaceutically active component comprises an anti-parasiticide which is a macrocyclic lactone or insect growth regulator, or mixtures thereof. 11. A sustained release apparatus according to claim 10 wherein the macrocyclic lactone component is ivermectin. 12. A sustained release apparatus according to claim 1, wherein the pharmaceutical carrier comprises a water-soluble substance which is in a solid state in the pharmaceutically active composition at the body temperature of an animal to which it is to be administered. 13. A sustained release apparatus according to claim 3, wherein the sustained release support material comprises a silicone material. 14. A sustained release apparatus according to claim 13, wherein the sustained release support material comprises a solid absorption medium which is selected from a fumed silica or porous silica or mixture thereof, the pharmaceutically active component being introduced into the silica. 15. A sustained release kit comprising a plurality of sustained release mini tablet implants packaged for delivery in a single treatment, each mini tablet implant comprising a pharmaceutically active composition comprising at least one pharmaceutically active component; anda carrier therefor;wherein the carrier is a sugar or mineral salt or mixture thereof,wherein each mini tablet implant is of the coated tablet type;each mini tablet implant being approximately 0.1 to 0.5 times the length and/or diameter of a single immediate release tablet capable of providing the desired threshold blood level depending on the pharmaceutically active component selected, andhaving a payload of approximately 30% to 70% by weight of the total payload of an equivalent immediate release treatment conducted for an equivalent period;the sustained release apparatus providing, in use, zero order release of pharmaceutically active component;each mini-tablet implant being of insufficient size and/or payload individually to provide a predetermined desired threshold blood level of pharmaceutically active component for treatment of a selected indication. 16. A sustained release kit according to claim 15, further comprising a delivery apparatus including an injector instrument for subcutaneous or intramuscular delivery of implants. 17. A sustained release kit according to claim 15, wherein the pharmaceutically active component comprises one or more selected from the group consisting of cytokines, hematopoietic factors, hormones, growth factors, neurotrophic factors, fibroblast growth factor, and hepatocyte proliferation factor; cell adhesion factors; immunosuppressants; enzymes, blood coagulating factors, proteins involved in bone metabolism, vaccines and antibodies. 18. A sustained release anthelmintic apparatus comprising a plurality of sustained release compressed mini tablet implants; each mini tablet implant comprising an anthelmintic pharmaceutical composition comprising an anthelmintic component; anda non-silicone carrier therefor andan anthelmintic pharmaceutical composition comprising at least one anthelmintic pharmaceutical component; anda carrier therefor;wherein the carrier is a sugar or mineral acid or mixture thereof,wherein each mini tablet implant is of the coated tablet type;each mini tablet implant being approximately 0.1 to 0.5 times the length and/or diameter of a single immediate release tablet capable of providing the desired threshold blood level depending on the anthelmintic pharmaceutical component selected, andhaving a payload of approximately 30% to 70% by weight of the total payload of an equivalent immediate release treatment conducted for an equivalent period;the sustained release apparatus providing, in use, zero order release of anthelmintic pharmaceutical component;each mini-tablet implant being of insufficient size and/or payload individually to provide a predetermined desired threshold blood level of pharmaceutically active component for treatment of a selected indication. 19. A sustained release anthelmintic apparatus according to claim 18, wherein the anthelmintic component comprises a macrocyclic lactone or insect growth regulator, or mixtures thereof. 20. A sustained release anthelmintic apparatus according to claim 19, wherein the macrocyclic lactone is ivermectin. 21. A method for the therapeutic or prophylactic treatment of a parasitic infection or a growth-related indication in an animal requiring such treatment, which method comprises administering to the animal a sustained release delivery apparatus comprising a plurality of sustained release mini tablet implants; each mini tablet implant comprising a pharmaceutically active composition comprising an anti-parasitic active or a growth-enhancing component; anda carrier therefor a carrier therefor;wherein the carrier is a sugar or mineral salt or mixture thereof,wherein each mini tablet implant is of the coated tablet type;each mini tablet implant being approximately 0.1 to 0.5 times the length and/or diameter of a single immediate release tablet capable of providing the desired threshold blood level depending on the pharmaceutical active component selected, andhaving a payload of approximately 30% to 70% by weight of the total payload of an equivalent immediate release treatment conducted for an equivalent period;the sustained release apparatus providing, in use, zero order release of pharmaceutical active component;each mini tablet implant being of insufficient size and/or payload individually to provide a predetermined required threshold blood level of pharmaceutically active component for treatment of a selected indication. 22. A method according to claim 21, wherein the animal to be treated is selected from the group consisting of sheep, cattle, goats, horses, camels, pigs, dogs, cats, ferrets, rabbits, marsupials, buffalos, yaks, primates, humans, birds including chickens, geese and turkeys, rodents including rats and mice, fish, reptiles and the like.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.